Ann Hsu

6.9k total citations · 1 hit paper
67 papers, 5.0k citations indexed

About

Ann Hsu is a scholar working on Infectious Diseases, Virology and Neurology. According to data from OpenAlex, Ann Hsu has authored 67 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Infectious Diseases, 29 papers in Virology and 17 papers in Neurology. Recurrent topics in Ann Hsu's work include HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (29 papers) and Parkinson's Disease Mechanisms and Treatments (17 papers). Ann Hsu is often cited by papers focused on HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (29 papers) and Parkinson's Disease Mechanisms and Treatments (17 papers). Ann Hsu collaborates with scholars based in United States, United Kingdom and Germany. Ann Hsu's co-authors include G. Richard Granneman, John M. Leonard, Richard Bertz, Dale J. Kempf, Eugene Sun, David D. Ho, Martin Markowitz, Joaquin Valdes, Suneel Gupta and Charles A. Boucher and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Neurology.

In The Last Decade

Ann Hsu

65 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1996 601 citations Akhteruzzaman Molla, Marina Korneyeva et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ann Hsu United States	30	3.5k	2.7k	866	566	558	67	5.0k
Graeme Moyle United Kingdom	44	4.9k 1.4×	3.8k 1.4×	2.4k 2.8×	363 0.6×	141 0.3×	217	6.9k
William Lewis United States	44	1.9k 0.6×	1.2k 0.5×	1.8k 2.0×	231 0.4×	115 0.2×	111	6.8k
Andrea Calcagno Italy	27	1.6k 0.5×	990 0.4×	773 0.9×	292 0.5×	77 0.1×	229	2.8k
David Nolan Australia	41	2.1k 0.6×	1.9k 0.7×	1.5k 1.7×	413 0.7×	34 0.1×	149	7.3k
Lı́dia Ruiz Spain	36	2.6k 0.7×	2.4k 0.9×	535 0.6×	265 0.5×	27 0.0×	102	4.4k
Alan Winston United Kingdom	39	2.5k 0.7×	2.4k 0.9×	1.7k 1.9×	275 0.5×	87 0.2×	198	4.2k
Peter P. Koopmans Netherlands	24	1.5k 0.4×	1.1k 0.4×	731 0.8×	275 0.5×	26 0.0×	54	2.5k
Qing Ma United States	29	709 0.2×	508 0.2×	361 0.4×	226 0.4×	134 0.2×	164	2.8k
Kenneth C. Cundy United States	27	839 0.2×	484 0.2×	82 0.1×	282 0.5×	239 0.4×	54	3.0k
Julie A. Stone United States	36	1.7k 0.5×	521 0.2×	139 0.2×	349 0.6×	40 0.1×	88	3.3k

Countries citing papers authored by Ann Hsu

Since Specialization

Citations

This map shows the geographic impact of Ann Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Hsu more than expected).

Fields of papers citing papers by Ann Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Hsu. The network helps show where Ann Hsu may publish in the future.

Co-authorship network of co-authors of Ann Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Hsu. A scholar is included among the top collaborators of Ann Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Hsu. Ann Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hsu, Ann, et al.. (2020). Variation of picture angles and its effect on the Concealed Information Test. Cognitive Research Principles and Implications. 5(1). 33–33. 3 indexed citations

Tetrud, James W., Paul A. Nausieda, Grace Liang, et al.. (2016). Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. Journal of the Neurological Sciences. 373. 116–123. 4 indexed citations

Hsu, Ann, et al.. (2015). Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet^®), sustained‐release carbidopa‐levodopa (Sinemet^® CR), and carbidopa‐levodopa‐entacapone (Stalevo^®). The Journal of Clinical Pharmacology. 55(9). 995–1003. 57 indexed citations

Hsu, Ann, et al.. (2015). Clinical Pharmacokinetics of IPX066. Clinical Neuropharmacology. 39(1). 10–17. 18 indexed citations

Stocchi, Fabrizio, Ann Hsu, Sarita Khanna, et al.. (2014). Comparison of IPX066 with carbidopa–levodopa plus entacapone in advanced PD patients. Parkinsonism & Related Disorders. 20(12). 1335–1340. 53 indexed citations

Shmukler, Boris E., Ann Hsu, Marie Trudel, et al.. (2013). N-ethylmaleimide activates a Cl−-independent component of K+ flux in mouse erythrocytes. Blood Cells Molecules and Diseases. 51(1). 9–16. 5 indexed citations

Sáez‐Llorens, Xavier, Richard A. Rode, Edward Handelsman, et al.. (2003). . The Pediatric Infectious Disease Journal. 22(3). 216–223. 5 indexed citations

Sáez‐Llorens, Xavier, Richard A. Rode, Perry Gomez, et al.. (2003). Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. The Pediatric Infectious Disease Journal. 22(3). 216–223. 102 indexed citations

Bertz, Richard, Barry Bernstein, Yi‐Lin Chiu, et al.. (2002). Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects. 42. 26. 5 indexed citations

10.

Hsu, Ann, Laura Williams, & Thomas N. Kakuda. (2001). The 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Expert Opinion on Pharmacotherapy. 2(8). 1339–1345. 14 indexed citations

11.

Buss, Neil, et al.. (2001). Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. British Journal of Clinical Pharmacology. 52(3). 255–264. 61 indexed citations

12.

Gustavson, Linda E., Richard Bertz, Ann Hsu, et al.. (2000). Assessment of the bioequivalence and food effects for liquid and soft elastic capsule co-formulations of ABT-378/ritonavir in healthy subjects. 40. 338. 8 indexed citations

13.

Bertz, Richard, et al.. (2000). Assessment of the pharmacokinetic interaction between ABT-378/ritonavir and efavirenz in healthy volunteers and in HIV + subjects. 40. 14. 1 indexed citations

14.

Ouellet, Danièle, Ann Hsu, G. Richard Granneman, et al.. (1998). Pharmacokinetic interaction between ritonavir and clarithromycin*. Clinical Pharmacology & Therapeutics. 64(4). 355–362. 64 indexed citations

15.

Cato, Allen, John C. Cavanaugh, Harry Shi, et al.. (1998). The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin*. Clinical Pharmacology & Therapeutics. 63(4). 414–421. 54 indexed citations

16.

Ouellet, Danièle, Ann Hsu, Jiang Qian, et al.. (1998). Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. British Journal of Clinical Pharmacology. 46(2). 111–116. 143 indexed citations

17.

Cato, Allen, Jiang Qian, Ann Hsu, et al.. (1998). Pharmacokinetic Interaction Between Ritonavir and Didanosine When Administered Concurrently to HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 18(5). 466–472. 10 indexed citations

18.

Molla, Akhteruzzaman, Marina Korneyeva, Qing Gao, et al.. (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine. 2(7). 760–766. 601 indexed citations breakdown →

19.

Markowitz, Martin, Michael S. Saag, William G. Powderly, et al.. (1995). A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection. New England Journal of Medicine. 333(23). 1534–1540. 403 indexed citations

20.

Danner, Sven A., Andrew Carr, John M. Leonard, et al.. (1995). A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease. New England Journal of Medicine. 333(23). 1528–1534. 472 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact